A pilot study on the use of interferon beta-1a in early Alzheimer’s disease subjects

Journal of Neuroinflammation

Andrea Paolillo¹  Giuseppe Bruno²  Stefano Ruggieri³  Anna Elisa Castellano⁴  Francesco Iemolo³  Giuseppe Zappalà⁵  Luigi Maria Edoardo Grimaldi⁶ 

[1] MerckSerono S.A., Merck Serono-Italy An affiliate of Merck KGA, Darmsdadt, Germany, Via Casilina 125, 00176 Roma, Italy;Centro U.V.A., Dipartimento di Scienze Neurologiche, Università degli Studi di Roma “La Sapienza”, Viale dell’Università, 30, 00185 Roma, Italy;U.O.C. Provinciale di Neurologia, Via Papa Giovanni XIII, 97019 Vittoria, RG, Italy;Clinica Neurologica, IRCCS Neuromed, Via Atinense, 18, 86077 Pozzilli, IS, Italy;U.V.A. Neurologia, Azienda Ospedaliera Garibaldi-Nesima, Via Palermo 135, 95122 Catania, Italy;U.O. di Neurologia, Fondazione Istituto San Raffaele “G. Giglio” di Cefalù, Contrada Pietrapollastra, 90015 Cefalù, PA, Italy

关键词: interferon;    multiple sclerosis;    controlled;    randomized;    clinical trials;    Alzheimer’s disease;   

Others  :  824744
DOI  :  10.1186/1742-2094-11-30

 received in 2013-11-11, accepted in 2014-01-26,  发布年份 2014

【 摘 要 】

Despite the fact that multiple sclerosis (MS) and Alzheimer’s disease (AD) share common neuroimmunological features, interferon beta 1a (IFNβ1a), the well-established treatment for the prevention of disease progression and cognitive decline in MS patients, has never been used in AD. We evaluated the safety and efficacy of IFNβ1a in subjects affected by mild-to-moderate AD in a double-blind, randomized, placebo-controlled, multicenter pilot study. Forty-two early Alzheimer’s patients were randomized to receive either a 22 mcg subcutaneous injection of IFNβ1a or placebo three times per week. A treatment period of 28 weeks was followed by 24 weeks of observation. IFNβ1a was well tolerated and adverse events were infrequent and mild to moderate. Although not statistically significant, a reduction in disease progression during follow-up was measured in IFNβ1a-treated patients by the Alzheimer’s Disease Assessment Scale cognitive subscale. Interestingly, the treatment group showed significant improvements in the Instrumental Activities of Daily Living and Physical Self-maintenance Scale. This study suggests that IFNβ1a is safe and well tolerated in early AD patients, and its possible beneficial role should be further investigated in larger studies.

【 授权许可】

   
2014 Grimaldi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Bishop NA, Lu T, Yankner BA: Neural mechanisms of ageing and cognitive decline. Nature 2010, 464:529-535.
• [2]Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA: Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003, 60:1119-1122.
• [3]De Strooper B: Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev 2010, 90:465-494.
• [4]Kalaria RN: Microglia and Alzheimer’s disease. Curr Opin Hematol 1999, 6:15-24.
• [5]McGeer PL, McGeer EG: The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995, 21:195-218.
• [6]Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL III, Araoz C: Brain interleukin 1 and S-100 immunoreactivity are elevated in down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 1989, 86:7611-7615.
• [7]Kalaria RN: The blood–brain barrier and cerebrovascular pathology in Alzheimer’s disease. Ann N Y Acad Sci 1999, 893:113-125.
• [8]Ferguson B, Matyszak MK, Esiri MM, Perry VH: Axonal damage in acute multiple sclerosis lesions. Brain 1997, 120(Pt 3):393-399.
• [9]Huang YM, Xiao BG, Ozenci V, Kouwenhoven M, Teleshova N, Fredrikson S, Link H: Multiple sclerosis is associated with high levels of circulating dendritic cells secreting pro-inflammatory cytokines. J Neuroimmunol 1999, 99:82-90.
• [10]Trapp BD, Nave KA: Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008, 31:247-269.
• [11]Weissert R, Svenningsson A, Lobell A, de Graaf KL, Andersson R, Olsson T: Molecular and genetic requirements for preferential recruitment of TCRBV8S2+ T cells in Lewis rat experimental autoimmune encephalomyelitis. J Immunol 1998, 160:681-690.
• [12]Manfredonia F, Pasquali L, Dardano A, Iudice A, Murri L, Monzani F: Review of the clinical evidence for interferon beta 1a (Rebif) in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat 2008, 4:321-336.
• [13]Rothuizen LE, Buclin T, Spertini F, Trinchard I, Munafo A, Buchwalder PA, Ythier A, Biollaz J: Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers. J Neuroimmunol 1999, 99:131-141.
• [14]Yong VW, Chabot S, Stuve O, Williams G: Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998, 51:682-689.
• [15]Dhib-Jalbut S: Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 2002, 58(Suppl 4):S3-S9.
• [16]Galboiz Y, Shapiro S, Lahat N, Rawashdeh H, Miller A: Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann Neurol 2001, 50:443-451.
• [17]Biernacki K, Antel JP, Blain M, Narayanan S, Arnold DL, Prat A: Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch Neurol 2005, 62:563-568.
• [18]Sattler MB, Demmer I, Williams SK, Maier K, Merkler D, Gadjanski I, Stadelmann C, Bahr M, Diem R: Effects of interferon-beta-1a on neuronal survival under autoimmune inflammatory conditions. Exp Neurol 2006, 201:172-181.
• [19]Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M, COGIMUS Study Group: Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. Mult Scler 2010, 16:68-77.
• [20]Fernández PL, Britton GB, Rao KS: Potential immunotargets for Alzheimer’s disease treatment strategies. J Alzheimers Dis 2013, 33:297-312.
• [21]Hensley K: Neuroinflammation in Alzheimer’s disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. J Alzheimers Dis 2010, 21:1-14.
• [22]Tullman MJ: A review of current and emerging therapeutic strategies in multiple sclerosis. Am J Manag Care 2013, 19(Suppl):s21-s27.
• [23]Patten SB, Francis G, Metz LM, Lopez-Bresnahan M, Chang P, Curtin F: The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Mult Scler 2005, 11:175-181.
• [24]Candore G, Bulati M, Caruso C, Castiglia L, Colonna-Romano G, Di Bona D, Duro G, Lio D, Matranga D, Pellicano M, Rizzo C, Scapagnini G, Vasto S: Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications. Rejuvenation Res 2010, 13:301-313.
• [25]Ullrich C, Pirchl M, Humpel C: Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits. Mol Cell Neurosci 2010, 45:408-417.
• [26]Weinstock-Guttman B, Zivadinov R, Horakova D, Havrdova E, Qu J, Shyh G, Lakota E, O’Connor K, Badgett D, Tamaño-Blanco M, Tyblova M, Hussein S, Bergsland N, Willis L, Krasensky J, Vaneckova M, Seidl Z, Ramanathan M: Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry 2013, 84:1186-1191.